Considere intervenções destinadas a modificar os fatores de risco a fim de retardar ou prevenir o início da insuficiência cardíaca aguda, incluindo:[1]McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599-726.
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
http://www.ncbi.nlm.nih.gov/pubmed/34447992?tool=bestpractice.com
Doença arterial coronariana: controle com aspirina, betabloqueadores, estatinas e inibidores da ECA, conforme necessário
A otimização do tratamento da hipertensão, o abandono do hábito de fumar e o controle de lipídios proporcionam um benefício substancial aos pacientes com doença arterial coronariana.[1]McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599-726.
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
http://www.ncbi.nlm.nih.gov/pubmed/34447992?tool=bestpractice.com
O controle ideal da hipertensão geralmente requer mais de um medicamento anti-hipertensivo.[23]Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023 Dec 1;41(12):1874-2071.
https://journals.lww.com/jhypertension/fulltext/2023/12000/2023_esh_guidelines_for_the_management_of_arterial.2.aspx
http://www.ncbi.nlm.nih.gov/pubmed/37345492?tool=bestpractice.com
Diferentes medicamentos anti-hipertensivos (diuréticos, inibidores da ECA, bloqueadores dos receptores da angiotensina, betabloqueadores, bloqueadores dos canais de cálcio) têm se mostrado eficazes, especialmente em idosos, com e sem história de infarto do miocárdio.[1]McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599-726.
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
http://www.ncbi.nlm.nih.gov/pubmed/34447992?tool=bestpractice.com
Diabetes mellitus: além do controle metabólico, garanta o controle agressivo dos lipídios e da pressão arterial.[24]Yusuf S, Sleight P, Pogue J, et al; the Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000 Jan 20;342(3):145-53.
http://www.nejm.org/doi/full/10.1056/NEJM200001203420301#t=article
http://www.ncbi.nlm.nih.gov/pubmed/10639539?tool=bestpractice.com
Use inibidores da proteína cotransportadora de sódio e glicose 2 (SGLT2) (por exemplo, dapagliflozina ou empagliflozina) para pacientes com diabetes do tipo 2 e doença cardiovascular estabelecida ou com alto risco cardiovascular para evitar hospitalizações por insuficiência cardíaca, independentemente de eles terem um diagnóstico de insuficiência cardíaca existente (ICFEP ou ICFER).[1]McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599-726.
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
http://www.ncbi.nlm.nih.gov/pubmed/34447992?tool=bestpractice.com
[2]Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation. 2022 May 3;145(18):e895-1032.
https://www.ahajournals.org/doi/full/10.1161/CIR.0000000000001063
http://www.ncbi.nlm.nih.gov/pubmed/35363499?tool=bestpractice.com
Pacientes com diabetes que tomam inibidores de SGLT2 têm maior risco de desenvolver cetoacidose diabética (incluindo cetoacidose euglicêmica).[25]Musso G, Saba F, Cassader M, et al. Diabetic ketoacidosis with SGLT2 inhibitors. BMJ. 2020 Nov 12;371:m4147.
https://www.doi.org/10.1136/bmj.m4147
http://www.ncbi.nlm.nih.gov/pubmed/33184044?tool=bestpractice.com
Consumo de álcool e ingestão excessiva de sal e líquidos: desencorajar em pacientes com disfunção ventricular esquerda conhecida.[1]McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599-726.
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
http://www.ncbi.nlm.nih.gov/pubmed/34447992?tool=bestpractice.com
Medicamentos que podem causar ou potencializar a insuficiência cardíaca: evite, se for seguro e possível, fazê-lo.[26]Page RL, O'Bryant CL, Cheng D, et al. Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association. Circulation. 2016 Aug 9;134(6):e32-69.
http://circ.ahajournals.org/content/134/6/e32.long
http://www.ncbi.nlm.nih.gov/pubmed/27400984?tool=bestpractice.com
Recomenda-se que todos os pacientes com insuficiência cardíaca sejam submetidos à vacinação pneumocócica, COVID-19 e influenza anual.[1]McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599-726.
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
http://www.ncbi.nlm.nih.gov/pubmed/34447992?tool=bestpractice.com
[87]Girerd N, Chapet N, Roubille C, et al. Vaccination for respiratory infections in patients with heart failure. J Clin Med. 2021 Sep 22;10(19):4311.
https://pmc.ncbi.nlm.nih.gov/articles/PMC8509310
http://www.ncbi.nlm.nih.gov/pubmed/34640328?tool=bestpractice.com